Alemtuzumab

證據等級: L5

預測適應症: 10 個

Alemtuzumab: From CLL and Multiple Sclerosis to Syndrome with Combined Immunodeficiency

One-Sentence Summary

Alemtuzumab (Campath/Lemtrada) is an anti-CD52 monoclonal antibody used internationally for B-cell chronic lymphocytic leukemia (CLL) and relapsing multiple sclerosis, working by rapidly and profoundly depleting CD52-bearing lymphocytes throughout the body. The TxGNN model predicts it may be effective for Syndrome with Combined Immunodeficiency — primarily as a reduced-intensity conditioning agent in allogeneic hematopoietic stem cell transplantation (HSCT) — with 13 clinical trials and 12 publications currently supporting this direction.

Note: The highest TxGNN-scoring prediction (Rank 1: Hepatic Infarction, score 94.44%) was assessed as Hold / L5 with no clinical or mechanistic evidence, and no supporting trials or literature. This report therefore features Rank 2 (Syndrome with Combined Immunodeficiency, score 93.73%), which carries the strongest actionable evidence base.

Quick Overview

Item	Content
Original Indication	B-cell CLL; relapsing multiple sclerosis (not registered in Singapore — no local license data available)
Predicted New Indication	Syndrome with Combined Immunodeficiency
TxGNN Prediction Score	93.73%
Evidence Level	L2
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Singapore HSA registry, as Alemtuzumab is not locally registered. Based on available clinical and scientific evidence, Alemtuzumab is a humanized IgG1 monoclonal antibody that binds to CD52 — a glycoprotein densely expressed on the surface of T lymphocytes, B lymphocytes, NK cells, and monocytes. Upon binding, it triggers complement-mediated cytolysis, antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptotic signalling, resulting in profound, prolonged lymphocyte depletion. In CLL, this eliminates malignant B cells; in multiple sclerosis, it drives an immune "reset" by ablating autoreactive T-cell populations.

Syndrome with combined immunodeficiency encompasses a spectrum of genetic disorders — including SCID, XIAP deficiency, Hyper-IgM syndrome, Wiskott-Aldrich syndrome, and chronic granulomatous disease — defined by severe dysfunction or absence of T and/or B lymphocytes. Allogeneic HSCT is the only established cure, but its success depends critically on eliminating the host's dysfunctional immune cells before donor engraftment. Alemtuzumab's mechanism directly addresses this need: its lymphodepleting action clears defective host lymphocytes with substantially less collateral organ toxicity than traditional myeloablative conditioning (busulfan/cyclophosphamide), thereby reducing graft-versus-host disease (GvHD) risk while creating the immunological space required for donor hematopoietic reconstitution.

This mechanistic bridge is directly supported by multiple clinical programs spanning nearly two decades. A completed Phase 2/3 trial (NCT01019876, n=38) demonstrated risk-adapted, Alemtuzumab-based reduced-intensity conditioning (RIC) in immunodeficiency and non-malignant disorders, and a currently recruiting Phase 2 study (NCT01962415, n=100) is expected to generate the strongest prospective efficacy evidence to date. The primary safety concern is the depth of lymphodepletion: opportunistic infections — particularly EBV and CMV reactivation — become a competing risk that demands rigorous prophylaxis and surveillance protocols in any planned clinical application.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01019876	Phase 2/3	Completed	38	Risk-adapted allo-SCT with Alemtuzumab-based RIC for non-malignant diseases including immunodeficiencies; the highest-grade completed trial in this indication, providing both efficacy and safety data
NCT01962415	Phase 2	Recruiting	100	RIC-HSCT (cord blood/BM/PBSC) for pediatric and young adult (≤55 yr) primary immunodeficiency; largest ongoing study, will yield current strongest prospective evidence
NCT01652092	N/A	Active, not recruiting	57	Standard-of-care allo-HSCT guideline study for primary immune deficiencies; Alemtuzumab is one of the permitted conditioning options, generating real-world safety data
NCT07284641	Phase 2	Recruiting	25	HSCT with RIC/TBI for CVID and autoimmune manifestations of primary immune regulatory disorders; extends Alemtuzumab-based HSCT to additional combined immunodeficiency subtypes
NCT05463133	Phase 1/2	Recruiting	50	Alemtuzumab + Busulfan + TBI conditioning for chronic granulomatous disease, combined with IL-6/IFN-γ antagonists to improve transplant outcomes
NCT01182675	Phase 2	Terminated	7	Alemtuzumab + Plerixafor/Filgrastim mobilization for SCID children, eliminating toxic chemotherapy conditioning; early termination limits conclusions but provides safety signals
NCT02512679	Phase 2	Terminated	20	Related-donor HSCT for genetic lymphohematopoietic diseases including combined immune deficiency; provides safety data for donor selection strategies despite early termination
NCT00579137	Phase 1/2	Terminated	3	Alemtuzumab + anti-CD45 mAb as the sole conditioning regimen for allo-SCT in SCID and other primary immunodeficiency; direct proof-of-concept for antibody-only conditioning, though very small sample
NCT04528355	N/A	Recruiting	50	Prospective outcomes study examining simplified Alemtuzumab dosing strata in RIC-HSCT for non-malignant disorders; generates real-world pharmacokinetic and engraftment data
NCT01821781	Phase 2	Active, not recruiting	20	RIC-HSCT for immune function disorders, testing whether maximizing host immune suppression with Alemtuzumab reduces graft rejection and optimizes donor engraftment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29155317	2018	Multicenter Cohort	Biol Blood Marrow Transplant	160 children with primary immunodeficiency receiving treosulfan + fludarabine ± Alemtuzumab conditioning for HSCT; better T-cell chimerism and lower toxicity than cyclophosphamide-based regimens
21325599	2011	Multicenter Cohort	Blood	70 children with primary immunodeficiency; treosulfan + fludarabine + Alemtuzumab conditioning demonstrated less veno-occlusive disease than busulfan and did not require pharmacokinetic monitoring
23131490	2013	International Retrospective Survey	Blood	19 XIAP-deficient patients; 11 received Alemtuzumab-predominant RIC; highlights both the feasibility and challenges of Alemtuzumab-based HSCT in severe combined immunodeficiency subtypes
27543157	2016	Single-Center Cohort	Biol Blood Marrow Transplant	Direct comparison of Alemtuzumab + Fludarabine + Melphalan RIC vs. myeloablative Bu/Cy/ATG for chronic granulomatous disease; RIC yielded lower toxicity with acceptable chimerism stability
26073206	2015	Case Series	Pediatr Transplant	5 Hyper-IgM syndrome (CD40L deficiency) patients undergoing HSCT; confirms the curative potential of transplantation in humoral combined immunodeficiency, median transplant age 41 months
18940685	2008	Case Series	Biol Blood Marrow Transplant	Alemtuzumab (Campath-1H) + Fludarabine non-myeloablative conditioning successfully rescued 12 pediatric patients with HSCT graft failure, including 4 SCID cases; demonstrates salvage applicability
11841458	2002	Case Report	Br J Haematol	Non-myeloablative Alemtuzumab-based BMT in a 26-year-old with Wiskott-Aldrich syndrome; partial engraftment and immune restoration achieved despite severe pre-existing infections and vasculitis
19471859	2009	Case Report	Immunol Res	Alemtuzumab-based RIC-HSCT for IPEX syndrome (FOXP3 mutation); FOXP3+ T regulatory cell reconstitution observed post-transplant, correlating with clinical improvement
35065305	2022	Diagnostic Review	Clin Immunol	Novel RFXANK mutation causing bare lymphocyte syndrome type II presenting with SCID-like phenotype; illustrates the diagnostic complexity within the combined immunodeficiency spectrum relevant to patient selection
15590388	2004	Adverse Event Analysis	Haematologica	Comprehensive review of infectious toxicity with Alemtuzumab; critical safety reference for designing mandatory infection prophylaxis and CMV/EBV surveillance protocols in any HSCT program

Singapore Market Information

Alemtuzumab is not currently registered with the Health Sciences Authority (HSA) of Singapore. No license records are available.

Authorization Number	Product Name	Dosage Form	Approved Indication
Not registered	—	—	—

Clinical access in Singapore would require application via HSA's Special Access Route (SAR). For reference, the drug holds the following international registrations:

Lemtrada (Sanofi, alemtuzumab 12 mg/1.2 mL concentrate for infusion): Approved by EMA (2013) and FDA (2014) for relapsing forms of multiple sclerosis
Campath (Genzyme, alemtuzumab 30 mg/1 mL concentrate for infusion): FDA-approved for B-cell CLL; commercially withdrawn from the EU market but accessible via named-patient programmes

Cytotoxicity

Alemtuzumab is approved for B-cell chronic lymphocytic leukemia (a hematological malignancy), and is therefore classified as an antineoplastic agent. It is a targeted monoclonal antibody — not a conventional cytotoxic chemotherapy drug.

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotherapy (anti-CD52 humanized IgG1 monoclonal antibody; not an alkylating agent, antimetabolite, or cytotoxic small molecule)
Myelosuppression Risk	High — profound and prolonged lymphopenia is the drug's primary mechanism of action; thrombocytopenia and neutropenia may also occur; full immune reconstitution can take 12–36 months
Emetogenicity Classification	Low
Monitoring Items	CBC with differential; lymphocyte subset counts (CD4+, CD8+, CD19+, NK cells); CMV and EBV PCR (weekly during the first year post-conditioning); thyroid function (TSH, fT4, anti-TPO antibodies); renal function
Handling Protection	Standard biologic / monoclonal antibody handling precautions apply; not classified as a hazardous cytotoxic drug for pharmacy handling under NIOSH or ISOPP guidelines

Safety Considerations

Safety data specific to Singapore's regulatory database is unavailable, as Alemtuzumab is not locally marketed. The following key safety signals are derived from the clinical trial evidence reviewed:

Infectious Risk: Profound lymphodepletion markedly increases susceptibility to opportunistic infections. CMV and EBV reactivation, pneumocystis pneumonia (PCP), and invasive fungal infections are the most significant risks. Structured prophylaxis (antiviral, antifungal, co-trimoxazole) and weekly PCR surveillance are mandatory in any clinical use (PMID 15590388).
Infusion-Related Reactions: Cytokine release syndrome can occur, particularly with the first infusion. Premedication with corticosteroids, antihistamines, and antipyretics is required.
Secondary Autoimmunity: Long-term use in MS is associated with secondary autoimmune sequelae — thyroid disorders, immune thrombocytopenia, and nephropathy — occurring months to years after treatment. Surveillance applies in any long-term clinical programme.

Please refer to the full Lemtrada or Campath prescribing information (EMA EPAR or FDA label) for comprehensive contraindications, drug interaction data, and risk management guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 1/2 clinical trials and multi-centre cohort studies spanning two decades establish a credible evidence base for Alemtuzumab as a reduced-intensity conditioning agent for HSCT in syndrome with combined immunodeficiency. A completed Phase 2/3 trial (NCT01019876) and a currently recruiting Phase 2 study targeting 100 patients (NCT01962415) provide the structural foundation for clinical development. The mechanistic rationale is direct and well-understood. However, the preponderance of small-sample and early-terminated studies, combined with significant infectious mortality risk, require carefully monitored implementation within a specialist transplant centre.

To proceed, the following is needed:

Apply for drug access via HSA Special Access Route (SAR) or named-patient importation from an EMA/FDA-registered supplier
Obtain detailed MOA and full prescribing information via DrugBank API and EMA EPAR for Lemtrada
Define a formal institutional protocol specifying: patient eligibility (SCID subtype, age, prior therapy, donor availability), Alemtuzumab dosing strategy (typically cumulative 1 mg/kg in RIC regimens), conditioning backbone drugs, and engraftment monitoring endpoints
Establish a mandatory infectious prophylaxis and surveillance programme: co-trimoxazole (PCP), acyclovir or ganciclovir (EBV/CMV), antifungal prophylaxis, and weekly CMV/EBV PCR for at least 12 months
Form a multi-disciplinary team: bone marrow transplant haematologist, clinical immunologist, paediatric infectious disease specialist, and transplant pharmacist
Obtain institutional ethics committee approval and HSA regulatory clearance before any clinical use in this unlicensed indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.